U.S. patent application number 12/173244 was filed with the patent office on 2009-09-24 for preventive/remedy for arteriosclerosis.
This patent application is currently assigned to JAPAN SCIENCE AND TECHNOLOGY AGENCY. Invention is credited to Yasushi IMAI, Takashi KADOWAKI, Naoto KUBOTA, Tetsuya KUBOTA, Ryozo NAGAI, Tetsuo NODA, Yasuo TERAUCHI, Toshimasa YAMAUCHI.
Application Number | 20090239938 12/173244 |
Document ID | / |
Family ID | 29561246 |
Filed Date | 2009-09-24 |
United States Patent
Application |
20090239938 |
Kind Code |
A1 |
KADOWAKI; Takashi ; et
al. |
September 24, 2009 |
PREVENTIVE/REMEDY FOR ARTERIOSCLEROSIS
Abstract
A scavenger receptor A expression down-regulator and a drug for
preventing or treating arteriosclerosis which contain, as the
active ingredient, a C-terminal globular domain of adiponectin,
adiponectin, or a gene encoding the domain or adiponectin.
According to the present invention, there is provided a preventive
or therapeutic agent capable of directly preventing intimal
thickening, which constitutes an essential feature of
arteriosclerosis. This effect can be attained through arresting the
onset and development of arteriosclerosis by reducing the
expression level of scavenger receptor A in arterial walls and
preventing lipid buildup in macrophages.
Inventors: |
KADOWAKI; Takashi; (Tokyo,
JP) ; YAMAUCHI; Toshimasa; (Tokyo, JP) ;
KUBOTA; Naoto; (Tokyo, JP) ; TERAUCHI; Yasuo;
(Tokyo, JP) ; KUBOTA; Tetsuya; (Tokyo, JP)
; NODA; Tetsuo; (Tokyo, JP) ; NAGAI; Ryozo;
(Tokyo, JP) ; IMAI; Yasushi; (Tokyo, JP) |
Correspondence
Address: |
OBLON, SPIVAK, MCCLELLAND MAIER & NEUSTADT, P.C.
1940 DUKE STREET
ALEXANDRIA
VA
22314
US
|
Assignee: |
JAPAN SCIENCE AND TECHNOLOGY
AGENCY
Saitama
JP
|
Family ID: |
29561246 |
Appl. No.: |
12/173244 |
Filed: |
July 15, 2008 |
Related U.S. Patent Documents
|
|
|
|
|
|
Application
Number |
Filing Date |
Patent Number |
|
|
10514715 |
Nov 23, 2004 |
7419955 |
|
|
PCT/JP03/06518 |
May 26, 2003 |
|
|
|
12173244 |
|
|
|
|
Current U.S.
Class: |
514/44R |
Current CPC
Class: |
A61K 38/2264 20130101;
A61K 48/00 20130101; A61P 9/10 20180101; A61P 43/00 20180101 |
Class at
Publication: |
514/44.R |
International
Class: |
A61K 31/7088 20060101
A61K031/7088 |
Foreign Application Data
Date |
Code |
Application Number |
May 24, 2002 |
JP |
2002/151220 |
Claims
1-9. (canceled)
10. A method for treating arteriosclerosis, comprising
administering a polynucleotide encoding a C-terminal globular
domain of adiponectin, in an effective amount to a subject in need
thereof to treat arteriosclerosis.
11. (canceled)
12. A method for down-regulating expression of scavenger receptor A
in a subject, comprising administering a polynucleotide encoding a
C-terminal globular domain of adiponectin, in an effective amount
to the subject to down-regulate expression of scavenger receptor
A.
13. (canceled)
14. The method as claimed in claim 10, wherein the polynucleotide
encodes amino acids 114 to 239 of SEQ ID NO:2.
15. The method as claimed in claim 10, wherein the polynucleotide
encodes amino acids 111 to 242 of SEQ ID NO:2.
16. The method as claimed in claim 12, wherein the polynucleotide
encodes amino acids 114 to 239 of SEQ ID NO:2.
17. The method as claimed in claim 12, wherein the polynucleotide
encodes amino acids 111 to 242 of SEQ ID NO:2.
18. The method as claimed in claim 10, wherein arteriosclerosis is
from intimal thickening.
19. The method as claimed in claim 10, wherein the polynucleotide
comprises nucleotides 387 to 717 of SEQ ID NO:1.
20. The method as claimed in claim 12, wherein the polynucleotide
comprises nucleotides 387 to 717 of SEQ ID NO:1.
21. The method as claimed in claim 10, wherein the polynucleotide
comprises nucleotides 333 to 726 of SEQ ID NO:1.
22. The method as claimed in claim 12, wherein the polynucleotide
comprises nucleotides 333 to 726 of SEQ ID NO: 1.
Description
TECHNICAL FIELD
[0001] The present invention relates to a drug for preventing or
treating arteriosclerosis.
BACKGROUND ART
[0002] The term "arteriosclerosis" refers to a pathological
condition where the walls of an artery lose elasticity and become
brittle. Arteriosclerosis is one of key factors causing aduet
diseases, including cerebral hemorrhage, cerebral infarction,
myocardial infarction, and nephrosclerosis. Known causes of
arteriosclerosis include hyperlipidemia, and bacteria, viruses, or
lipid peroxide in blood. However, the pathogenesis of
arteriosclerosis has not yet been fully elucidated. In any case,
since arteriosclerosis has been observed to begin with thickening
of arterial walls caused by damage to the arterial intima or
endothelium, there is keen demand for development of a drug capable
of inhibiting thickening of the arterial intima.
[0003] Accordingly, an object of the present invention is to
provide a drug which is effective for preventing or treating
arteriosclerosis.
DISCLOSURE OF THE INVENTION
[0004] Under the above circumstance, the present inventors have
devoted their research efforts to pharmacological actions of
adiponectin, which is known to have an insulin resistance reducing
effect, and have found that adiponectin-gene-deficient mice show
significantly thickened arterial intima; and that adiponectin, a
C-terminal globular domain thereof, or a gene thereof is useful as
a preventive or therapeutic drug for arteriosclerosis, on the basis
of their experimental results that when apoE-deficient mice, which
are employed as atherosclerosis onset model mice, are manipulated
to over-express adiponectin, in particular, the C-terminal globular
domain of adiponectin, the onset of arteriosclerosis is suppressed.
In addition, since over-expression of adiponectin lowers the
expression level of scavenger receptor A without significantly
affecting the levels of free fatty acid, neutral fat, or total
cholesterol in blood, the inventors have concluded that the
arteriosclerosis preventive action of adiponectin lowers the
expression level of scavenger receptor A, whereby accumulation of
lipids in macrophages is prevented. The present invention has been
accomplished on the basis of these findings.
[0005] Accordingly, the present invention provides a drug for
preventing or treating arteriosclerosis, the drug containing, as an
active ingredient thereof, a C-terminal globular domain of
adiponectin, adiponectin, or a gene encoding the C-terminal
globular domain of adiponectin or the adiponectin.
[0006] The present invention also provides a scavenger receptor A
expression down-regulator which contains, as an active ingredient
thereof, a C-terminal globular domain of adiponectin, adiponectin,
or a gene encoding the C-terminal globular domain of adiponectin or
the adiponectin.
[0007] The present invention also provides use, in the manufacture
of a drug for preventing or treating arteriosclerosis, of a
C-terminal globular domain of adiponectin, adiponectin, or a gene
encoding the C-terminal globular domain of adiponectin or the
adiponectin.
[0008] The present invention also provides use, in the manufacture
of a scavenger receptor A expression down-regulator, of a
C-terminal globular domain of adiponectin, adiponectin, or a gene
encoding the C-terminal globular domain of adiponectin or the
adiponectin.
[0009] The present invention also provides a method for treating
arteriosclerosis, comprising administering, to a subject in need
thereof, an effective amount of a C-terminal globular domain of
adiponectin, adiponectin, or a gene encoding the C-terminal
globular domain of adiponectin or the adiponectin.
[0010] The present invention also provides a method for
down-regulating the expression level of scavenger receptor A in a
patient, comprising administering to the patient an effective
amount of a C-terminal globular domain of adiponectin, adiponectin,
or a gene encoding the C-terminal globular domain of adiponectin or
the adiponectin.
BRIEF DESCRIPTION OF THE DRAWINGS
[0011] FIG. 1 schematically shows a gene targeting performed on
adiponectin gene deficiency, in which, a restriction map of a mouse
adiponectin gene (top), an adiponectin gene targeting vector
(middle), and a deduced targeting allele (bottom).
[0012] FIG. 2 shows the results of Southern blotting of
ES-cell-derived DNA samples which have been digested with SpeI and
EoRV. The bands of 17 kb are obtained from wild-type alleles, and
those of 10.5 kb are from mutated alleles.
[0013] FIG. 3 shows the results of Southern blotting of SpeI- and
EoRV-digested DNA samples from a wild-type mouse, a
hetero-deficient (adipo +/-) mouse, and a homo-deficient (adipo
-/-) mouse. The bands of 17 kb are obtained from wild-type alleles,
and those of 10.5 kb are from mutated alleles.
[0014] FIG. 4 shows the results of Northern blotting of white
adipose tissue samples from a wild-type mouse, a hetero-deficient
(adipo +/-) mouse, and a homo-deficient (adipo -/-) mouse.
[0015] FIG. 5 shows blood adiponectin level of a wild-type mouse, a
hetero-deficient (adipo +/-) mouse, and a homo-deficient (adipo
-/-) mouse. **P<0.01.
[0016] FIG. 6 shows blood leptin level of a wild-type mouse, a
hetero-deficient (adipo +/-) mouse, and a homo-deficient (adipo
-/-) mouse.
[0017] FIG. 7 shows the body weight, at 6 weeks of age, of a
wild-type mouse, a hetero-deficient (adipo +/-) mouse, and a
homo-deficient (adipo -/-) mouse.
[0018] FIG. 8 shows the results of an insulin tolerance test
performed on a wild-type mouse and a hetero-deficient (adipo +/-)
mouse at 6 weeks of age. *P<0.05.
[0019] FIG. 9 shows the results of a glucose tolerance test
performed on a wild-type mouse and a hetero-deficient (adipo +/-)
mouse at 6 weeks of age. *P<0.05.
[0020] FIG. 10 shows the results of a glucose tolerance test
performed on a wild-type mouse and a hetero-deficient (adipo +/-)
mouse after having loaded with a high-fat diet for 10 weeks.
*P<0.05, **P<0.01.
[0021] FIG. 11 shows the results of an insulin tolerance test
performed on a wild-type mouse and a homo-deficient (adipo -/-)
mouse, at 6 weeks of age. *P<0.05, **P<0.01.
[0022] FIG. 12 shows the results of a glucose tolerance test
performed on a wild-type mouse and a hetero-deficient (adipo +/-)
mouse, at 6 weeks of age. *P<0.05, **P<0.01.
[0023] FIG. 13 shows levels, in blood, of free fatty acid (FFA),
neutral fat (TG), total cholesterol (TC) of a wild-type mouse and a
hetero-deficient (adipo +/-) mouse.
[0024] FIG. 14 shows levels, in blood, of free fatty acid (FFA),
neutral fat (TG), total cholesterol (TC) of a wild-type mouse and a
homo-deficient (adipo -/-) mouse.
[0025] FIG. 15 shows the inner diameter of a blood vessel of a
wild-type mouse and a hetero-deficient (adipo +/-) mouse, as
measured two weeks after the mice underwent cuff placement.
[0026] FIG. 16 shows the degree of intimal thickening of a
wild-type mouse and a hetero-deficient (adipo +/-) mouse, as
measured two weeks after the mice underwent cuff placement.
[0027] FIG. 17 shows the degree of medial thickening of a wild-type
mouse and a hetero-deficient (adipo +/-) mouse, as measured two
weeks after the mice underwent cuff placement.
[0028] FIG. 18 shows the intima/media ratio of a wild-type mouse
and a hetero-deficient (adipo +/-) mouse, as measured two weeks
after the mice underwent cuff placement.
[0029] FIG. 19 shows the foci of arteriosclerosis in an
apoE-deficient (apoE-/-:a) mouse and a gAd-overexpressed
apoE-deficient (gAd Tg apoE-/-:b) mouse.
[0030] FIG. 20 shows the areas of the foci of arteriosclerosis in
an apoE-deficient (apoE-/-) mouse and a gAd-overexpressed
apoE-deficient (gAd Tg apoE-/-) mouse (aortic arch (b), descending
aorta (c), and their sum (a)).
[0031] FIG. 21 shows the results of Oil Red 0 staining, reaction
with anti-Mac3 antibody, and reaction with anti-scavenger receptor
A antibody as observed in an apoE-deficient (apoE-/-) mouse and a
gAd-overexpressed apoE-deficient (gAd Tg apoE-/-) mouse.
BEST MODE FOR CARRYING OUT THE INVENTION
[0032] Adiponectin, which is employed in the present invention, has
already been cloned (Maeda, K. et al., Biochem. Biophys. Res.
Commun. 221, 286-296 (1996), Nakano, Y. et al., J. Biochem. (Tokyo)
120, 802-812 (1996)), and is available through known means. SEQ ID
NOs: 1 and 2 show the nucleotide sequence and the amino acid
sequence of human adiponectin. Adiponectin is composed of an
N-terminal collagen-like sequence (cAd) a C-terminal globular
domain (gAd; in SEQ ID NO: 1, amino acid Nos. 114 to 239 or 111 to
242). The C-terminal globular domain (gAd) is preferred as it
provides stronger arteriosclerosis preventive and therapeutic
effects than full length adiponectin. SEQ ID NOs: 3 and 4 show the
nucleotide sequence and the amino acid sequence of mouse
adiponectin. The N-terminal collagen-like sequence (cAd) of the
mouse adiponectin stretches from 45 to 109 (amino acid No.), and
the C-terminal globular domain (gAd) stretches from 110 to 247
(amino acid No.). According to the present invention, not only
proteins comprising the amino acid sequence of any of SEQ ID NOs: 1
to 4 or an amino acid sequence having the gAd domain, but also a
protein comprising a modified amino acid sequence derived from
substitution, deletion, or addition of one or more amino acid
residues of any of these amino acid sequences may be employed, so
long as it provides an effect as exhibited by adiponectin. Examples
of such mutated proteins include those having 80% or higher
homology, preferably 90% or higher homology, to any of the amino
acid sequences of SEQ ID NOs: 1 to 4 or an amino acid sequence
including the gAd domain.
[0033] Examples of the gene which is employed in the present
invention include the genes coding for adiponectin (i.e., SEQ ID
NOs: 1 and 3) and a gene coding for gAd. Also, there may be
employed a gene having a nucleotide sequence capable of hybridizing
with any of these genes under stringent conditions.
[0034] Adiponectin or a polypeptide which forms a portion of
adiponectin (including gAd) may be isolated from cells containing
the same. However, since a gene coding for adiponectin has already
been cloned, the adiponectin or the polypeptide may be prepared
through a DNA recombinant technique; i.e., making use of
transformant cells created by use of expression vectors produced
through use of the gene.
[0035] As will be described hereinbelow, adiponectin-deficient mice
exhibit high levels of neutral fat in blood, but their cholesterol
levels are comparable to those of wild-type mice. Moreover,
adiponectin-deficient mice, representing an arteriosclerosis model,
exhibited intima thickening which was twice the thickness as
observed in wild-type mice. In contrast, when apoE-deficient mice,
which represent a spontaneous atherosclerosis model, are caused to
over-express gAd, they exhibit a significant reduction in
arteriosclerotic area, preventing development of arteriosclerosis.
However, overexpression of gAd induced in apoE-deficient mice only
insignificantly affect general risk factors for arteriosclerosis,
such as body weight and blood sugar, and free fatty acid, neutral
fat, and total cholesterol in blood. On the other hand,
over-expression of gAd induced in apoE-deficient mice was found to
exhibit a lowered expression of scavenger receptor A in arterial
walls. Scavenger receptor A is a receptor which, when macrophages
engulf modified LDL, binds to the modified LDL on the surface of a
cell, and is known to play a key role as a receptor which triggers
the onset of arteriosclerosis.
[0036] Accordingly, adiponectin, gAd, or a gene coding for
adiponectin or gAd is useful as a down-regulator of scavenger
receptor A expression, or as a drug for preventing or treating
arteriosclerosis. In particular, gAd or a gene encoding gAd is very
useful in that it exhibits a more potent down-regulating effect on
expression of a scavenger receptor as compared with adiponectin,
and stronger preventive or therapeutic effect.
[0037] For administering the drug of the present invention to a
mammal including a human, pharmaceutical compositions of a variety
of dosage forms may be produced through incorporation of a
pharmacologically acceptable carrier to any of the aforementioned
active ingredients. Among such dosage forms, preparations for
injection are preferred. Examples of the pharmacologically
acceptable carrier include distilled water, a solubilizer, a
stabilizer, an emulsifier, and a buffer. The dose of any of the
drugs may differ depending on the condition of the disease, sex,
body weight, etc., and may range from 0.1 .mu.g to 10 mg/day or
thereabouts, as reduced to the amount of adiponectin or gAd.
EXAMPLES
[0038] The present invention will next be described in more detail
by way of examples, which should not construed as limiting the
invention thereto.
A. Methods
(1) Preparation of Knockout Mice
[0039] Screening of a 129/Sv mouse genomic library was performed
using adiponectin cDNA as a probe, whereby a plurality of clones
harboring a gene encoding adiponectin were obtained. A targeting
vector was constructed, in which the region stretching from the
translation initiation site to the translation termination site had
been replaced by a neomycin-resistant gene. ES cells were
transfected with the resultant targeting vector. Screening was
performed through Southern blotting, whereby homologous
recombinants of 5 clones were confirmed. Chimeric mice were created
by means of microinjection, and the mice were crossbred with BI/6
to thereby produce F1, and then F2.
[0040] Briefly, an adiponectin-gene-deficient mouse was produced
through homologous recombination as shown in FIG. 1. With an aim to
knock out the mouse adiponectin gene, a targeting vector in which
exons 2 and 3 that encode adiponectin were replaced with a neo
resistant gene was prepared. Separate 5 homologous recombinant
clones were confirmed through Southern blotting (FIG. 2). From ES
cells having 129/Sv as a background, chimeric mice were produced,
and in order to create a hetero-deficient mouse, they were
cross-bred with BI/6. The genotype was confirmed through Southern
blotting (FIG. 3).
(2) Insulin Tolerance Test
[0041] Human insulin was intraperitoneally administered to test
mice in an amount of 0.7 mU per gram (body weight), and the mice
were fasted during the tolerance test. The blood was collected from
the tail vein, and blood sugar level was measured by means of a
Glutest Ace (registered trademark, product of Sanwa Kagaku
Kenkyusho Co., Ltd.).
(3) Glucose Tolerance Test
[0042] Glucose was perorally administered to test mice in an amount
of 1.5 mg per gram (body weight). Prior to the administration, the
mice had been fasted for at least 16 hours. The blood was collected
from the fundus vein, and blood sugar level and insulin level were
measured by means of a Glutest Ace (registered trademark, product
of Sanwa Kagaku Kenkyusho Co., Ltd.) and a rat insulin RIA kit
(product of Amersham Pharmacia Biotech), respectively.
(4) Measurement of Blood Lipid Level
[0043] After the test mice were fasted for 16 hours, levels of free
fatty acid, neutral fat, and total cholesterol, all in blood, were
measured by means of a NEFAC-test, a TGL-type, and a Tchol E-type
(product of Wako), respectively.
(5) Measurement of Blood Leptin Level and Blood Adiponectin
Level
[0044] After the mice were fasted for 16 hours, levels of leptin
and adiponectin, both in blood, were measured by means of a
Quintikine M kit (product of R&D) and an adiponectin RIA kit
(product of Linco), respectively.
(6) Creation of a Thick Vascular Intima Model Through Cuff
Placement
[0045] A 2.0-mm polyethylene tube (PE-50) was placed in the femoral
artery. When two weeks had passed, the artery was press-fixed with
formalin, and removed together with the opposite-side, uncuffed
artery, which served as a control artery. Each of the thus-removed
blood vessels was sliced to obtain continuous ring-shaped
specimens, each having a length of 10 mm. Ten specimens were taken
and HE staining was performed. The inner diameter of the blood
vessel, the thickness of the intima, and the thickness of the media
were measured, and intima/media ratio was calculated.
(7) Preparation of gAd-Overexpressed Mice
[0046] According to the method described in Diabetes 48, 1822-1829
(1999), a fused gene containing a human SAP promoter and mouse gAd
cDNA was prepared. Purified Hind III-XhoI fragments were
microinjected to pronuclei of fertilized ova of C57BL6 mice
(product of Clea Japan, Inc.). Tail DNA samples obtained from the
resultant transgenic mice were subjected to Southern blotting
through use of a gAd cDNA probe for the Bgl II/Hinc II site of gAd,
whereby gAd overexpression of the transgenic mice was
confirmed.
(8) Production of gAd-Overexpressing apoE-Deficient Mice
[0047] gAd-overexpressing apoE-deficient mice were crossbred, to
thereby produce gAd-overexpressing apoE-hetero-deficient mice. The
resultant mice were crossed further with apoE-deficient mice, to
thereby create apoE-deficient mice exhibiting over-expression of
gAd.
(9) Measurement of Blood Sugar Level and Lipid Level
[0048] Mice were fed until they were full, and their blood sugar
level and levels, in blood, of free fatty acid, neutral fat, and
total cholesterol were measured by means of a Glutest Ace
(registered trademark, product of Sanwa Kagaku Kenkyusyo Co.,
Ltd.), an NEFA C-test, a TGL-type, and a Tchol E-type (Products of
Wako), respectively.
(10) Evaluation of the Size of Arteriosclerotic Foci
[0049] From each of gAd-overexpressed apoE-deficient mice (4 months
old) and control apoE-deficient mice, the aortic arch and the
descending aorta were removed, fixed with formalin, and then
subjected to staining with Sudan IV. The arteriosclerotic foci were
evaluated in terms of their size.
(11) Evaluation in Terms of Buildup of Cholesterol Ester,
Expression Level of Scavenger Receptor A, and Macrophage
Accumulation
[0050] Frozen samples of continuous ring-shaped specimens of the
annulus portion of the aorta were prepared. Ten such samples were
subjected to immunostaining by use of Oil Red O, anti-scavenger
receptor A antibody, or anti-Mac3 antibody (a macrophage-specific
marker), whereby buildup of cholesterol ester, expression level of
scavenger receptor A, and macrophage accumulation were evaluated,
respectively.
B. Results
(1) Mouse-Adiponectin-Gene-Deficient Mice
[0051] Through Northern blotting of white adipose tissue, the
expression level of adiponectin in the hetero-deficient mice was
found to be reduced by about 60%, and the homo-deficient mice were
found to exhibit completely no adiponectin expression (FIG. 4).
Indeed, when blood adiponectin level was measured in the
hetero-deficient mice, the magnitude of reduction was found to be
about 60%, and the level in the hetero-deficient mice was found to
be lower than the undetectable level (FIG. 5). With respect to the
blood leptin level, no difference was observed (FIG. 6).
(2) Insulin Resistance of Mouse-Adiponectin-Gene-Deficient Mice
[0052] In three groups of 6-week-old mice; i.e., wild-type group,
hetero-deficient (adipo +/-) group, and homo-deficient (adipo -/-)
group, there was no difference in terms of body weight (FIG. 7).
The 6-week-old wild-type mice and hetero-defective mice of the same
age were subjected to an insulin tolerance test, to thereby check
their insulin sensitivity. The degree of reduction in blood sugar
level in response to exogenous insulin was statistically
significantly low in the hetero-deficient mice, proving that the
hetero-deficient mice had insulin resistance (FIG. 8).
[0053] Next, a glucose tolerance test was performed. No difference
was observed between the two groups of wild-type mice and
hetero-deficient mice in terms of blood sugar or insulin level
(FIG. 9). However, as compared with the wild-type mice, the
hetero-deficient mice, after having been loaded with 10-week high
fat diet, exhibited a significantly high blood sugar level before
and after loading with glucose, though the body weight remained in
a similar level (FIG. 10).
[0054] Afterwards, analysis on the homo-deficient mice was
performed.
[0055] An insulin tolerance test performed on 6-week-old wild-type
mice and homo-deficient mice of the same age. As compared with the
wild-type mice or the hetero-deficient mice, the degree of
reduction in blood sugar level in response to exogenous insulin was
statistically significantly low in the homo-deficient mice, proving
that the homo-deficient mice had insulin resistance higher than the
corresponding levels of the wild-type mice and homo-deficient mice
(FIG. 11).
[0056] Next, a glucose tolerance test was performed. In both stages
of during fasting and after glucose loading, the homo-deficient
mice exhibited blood sugar levels higher than the case of wild-type
mice. This substantiates that homo-deficient mice had slightly
impaired glucose tolerance in addition to insulin resistance (FIG.
12). Before administration and 30 minutes after administration, no
difference was observed between the wild-type group and the
homo-deficient group in terms of the insulin levels before and
after glucose loading. However, the homo-deficient mice showed a
somewhat low insulin level at 15 min (FIG. 12).
(3) Blood Neutral Fat Level in Adiponectin Homo-Deficient Mice
[0057] In order to check the effect of adiponectin on lipid
metabolism, levels, in blood, of free fatty acid (FFA), neutral fat
(TG), and total cholesterol (TC) were determined in wild-type,
hetero-deficient, and homo-deficient mice (FIGS. 13 and 14). The
hetero-deficient mice did not show any difference in level of any
of the three test items as compared with the wild-type mice (FIG.
13). However, the homo-deficient mice showed significantly higher
blood neutral fat levels than the wild-type mice (FIG. 14).
(4) Thickening of Intima in Cuff-Injured Models of Mouse
Adiponectin Hetero-Deficient Mice
[0058] In order to investigate the effect of adiponectin on
arteriosclerosis, the degree of intimal thickening induced by cuff
placement was measured in the wild-type mice and the
hetero-deficient mice for comparison therebetween. No difference
was observed between the two groups in terms of the vascular inner
diameter after cuff-induced injury was created (FIG. 15). When 2
weeks had elapsed after creation of cuff injury, the
hetero-deficient mice showed about 1.8 times the thickness of the
intima of the wild-type mice (FIG. 16). However, no difference was
observed between the two groups in terms of the thickness of the
media (FIG. 17). The intima/media ratio of the hetero-deficient
group exhibited a ratio about two-fold that of the wild-type mice
(FIG. 18).
(5) Prevention of the Onset of Arteriosclerosis in
gAd-Overexpressing apoE-Deficient Mice
[0059] ApoE-deficient mice, which represent a spontaneous
arteriosclerosis model, were caused to overexpress gAd and studied
whether or not onset of arteriosclerosis was prevented. The results
are shown in FIGS. 19 and 20. In FIG. 19, "a" shows the results of
Sudan IV staining of aorta samples from apoE-deficient mice, and
"b" shows the results of Sudan IV staining of aorta samples from
gAd-overexpressed apoE-deficient mice. As is evident from the
comparison between "a" and "b," gAd-overexpressed apoE-deficient
mice clearly show a reduction in the incidence of arteriosclerotic
foci. FIG. 20 shows comparison with respect to the area of
arteriosclerotic foci. FIG. 20 shows that over-expression of gAd
caused significant reduction in the area of arteriosclerotic foci,
which are stained with Sudan IV, in any case of aortic arch (b),
descending aorta (c), the sum of the mentioned two cases (a),
indicating arresting of the onset of arteriosclerosis.
(6) Effect of gAd Overexpression on Arteriosclerosis Risk Factors
in apoE-Deficient Mice on a Normal Diet
[0060] The body weight, blood sugar level, and levels, in blood, of
free fatty acid, neutral fat, and total cholesterol of
gAd-overexpressed apoE-deficient mice on a normal diet are shown in
Table 1.
TABLE-US-00001 TABLE 1 Mouse Statistical apoE-/- gAd Tg apoE-/-
significance Body weight(g) 29.8 .+-. 1.2 29.9 .+-. 1.5 none Plasma
glucose level (mg/dl) 145 .+-. 4 152 .+-. 8 none Serum total
cholesterol level (mg/dl) 541 .+-. 49 509 .+-. 32 none Serum
triglyceride level (mg/dl) 127 .+-. 52 104 .+-. 24 none Serum free
fatty acid level (mEq/L) 0.53 .+-. 0.08 0.57 .+-. 0.04 none Mean
.+-. s.e. (n = 5)
[0061] As shown in Table 1, when apoE-deficient mice on a normal
diet were caused to over-express gAd, no significant effect was
exerted on arteriosclerosis risk factors such as body weight and
blood sugar, and free fatty acid, neutral fat, and total
cholesterol in blood. This suggests that gAd possibly acts on
vascular walls or macrophages directly, to thereby exhibit
anti-arteriosclerotic activity.
(7) Mechanism of Arresting Onset of Arteriosclerosis by gAd
[0062] With an aim to elucidate the mechanism of the interaction
between gAd and vascular walls or macrophages, frozen samples of
continuous ring-shaped slices of annulus portion of the aorta were
subjected to immunostaining by use of Oil Red O, anti-scavenger
receptor A antibody, and a macrophage-specific marker; i.e.,
anti-Mac3 antibody. As a result, as shown in FIG. 21,
over-expression of gAd, though having no significant impact on
accumulation of macrophages, were found to reduce the expression
level of scavenger receptor A, suppress buildup of lipids in
macrophages, and arrest the onset of arteriosclerosis.
INDUSTRIAL APPLICABILITY
[0063] The present invention provides a preventive or therapeutic
agent capable of directly preventing intimal thickening, which
constitutes an essential feature of arteriosclerosis, wherein this
effect can be attained through arresting the onset and development
of arteriosclerosis by reducing the expression level of scavenger
receptor A in arterial walls and preventing lipid buildup in
macrophages.
Sequence CWU 1
1
41735DNAHomo sapiensCDS(1)..(735) 1atg ctg ttg ctg gga gct gtt cta
ctg cta tta gct ctg ccc ggt cat 48Met Leu Leu Leu Gly Ala Val Leu
Leu Leu Leu Ala Leu Pro Gly His1 5 10 15gac cag gaa acc acg act caa
ggg ccc gga gtc ctg ctt ccc ctg ccc 96Asp Gln Glu Thr Thr Thr Gln
Gly Pro Gly Val Leu Leu Pro Leu Pro 20 25 30aag ggg gcc tgc aca ggt
tgg atg gcg ggc atc cca ggg cat ccg ggc 144Lys Gly Ala Cys Thr Gly
Trp Met Ala Gly Ile Pro Gly His Pro Gly 35 40 45cat aat ggg gcc cca
ggc cgt gat ggc aga gat ggc acc cct ggt gag 192His Asn Gly Ala Pro
Gly Arg Asp Gly Arg Asp Gly Thr Pro Gly Glu 50 55 60aag ggt gag aaa
gga gat cca ggt ctt att ggt cct aag gga gac atc 240Lys Gly Glu Lys
Gly Asp Pro Gly Leu Ile Gly Pro Lys Gly Asp Ile65 70 75 80ggt gaa
acc gga gta ccc ggg gct gaa ggt ccc cga ggc ttt ccg gga 288Gly Glu
Thr Gly Val Pro Gly Ala Glu Gly Pro Arg Gly Phe Pro Gly 85 90 95atc
caa ggc agg aaa gga gaa cct gga gaa ggt gcc tat gta tac cgc 336Ile
Gln Gly Arg Lys Gly Glu Pro Gly Glu Gly Ala Tyr Val Tyr Arg 100 105
110tca gca ttc agt gtg gga ttg gag act tac gtt act atc ccc aac atg
384Ser Ala Phe Ser Val Gly Leu Glu Thr Tyr Val Thr Ile Pro Asn Met
115 120 125ccc att cgc ttt acc aag atc ttc tac aat cag caa aac cac
tat gat 432Pro Ile Arg Phe Thr Lys Ile Phe Tyr Asn Gln Gln Asn His
Tyr Asp 130 135 140ggc tcc act ggt aaa ttc cac tgc aac att cct ggg
ctg tac tac ttt 480Gly Ser Thr Gly Lys Phe His Cys Asn Ile Pro Gly
Leu Tyr Tyr Phe145 150 155 160gcc tac cac atc aca gtc tat atg aag
gat gtg aag gtc agc ctc ttc 528Ala Tyr His Ile Thr Val Tyr Met Lys
Asp Val Lys Val Ser Leu Phe 165 170 175aag aag gac aag gct atg ctc
ttc acc tat gat cag tac cag gaa aat 576Lys Lys Asp Lys Ala Met Leu
Phe Thr Tyr Asp Gln Tyr Gln Glu Asn 180 185 190aat gtg gac cag gcc
tcc ggc tct gtg ctc ctg cat ctg gag gtg ggc 624Asn Val Asp Gln Ala
Ser Gly Ser Val Leu Leu His Leu Glu Val Gly 195 200 205gac caa gtc
tgg ctc cag gtg tat ggg gaa gga gag cgt aat gga ctc 672Asp Gln Val
Trp Leu Gln Val Tyr Gly Glu Gly Glu Arg Asn Gly Leu 210 215 220tat
gct gat aat gac aat gac tcc acc ttc aca ggc ttt ctt ctc tac 720Tyr
Ala Asp Asn Asp Asn Asp Ser Thr Phe Thr Gly Phe Leu Leu Tyr225 230
235 240cat gac acc aac tga 735His Asp Thr Asn2244PRTHomo sapiens
2Met Leu Leu Leu Gly Ala Val Leu Leu Leu Leu Ala Leu Pro Gly His1 5
10 15Asp Gln Glu Thr Thr Thr Gln Gly Pro Gly Val Leu Leu Pro Leu
Pro 20 25 30Lys Gly Ala Cys Thr Gly Trp Met Ala Gly Ile Pro Gly His
Pro Gly 35 40 45His Asn Gly Ala Pro Gly Arg Asp Gly Arg Asp Gly Thr
Pro Gly Glu 50 55 60Lys Gly Glu Lys Gly Asp Pro Gly Leu Ile Gly Pro
Lys Gly Asp Ile65 70 75 80Gly Glu Thr Gly Val Pro Gly Ala Glu Gly
Pro Arg Gly Phe Pro Gly 85 90 95Ile Gln Gly Arg Lys Gly Glu Pro Gly
Glu Gly Ala Tyr Val Tyr Arg 100 105 110Ser Ala Phe Ser Val Gly Leu
Glu Thr Tyr Val Thr Ile Pro Asn Met 115 120 125Pro Ile Arg Phe Thr
Lys Ile Phe Tyr Asn Gln Gln Asn His Tyr Asp 130 135 140Gly Ser Thr
Gly Lys Phe His Cys Asn Ile Pro Gly Leu Tyr Tyr Phe145 150 155
160Ala Tyr His Ile Thr Val Tyr Met Lys Asp Val Lys Val Ser Leu Phe
165 170 175Lys Lys Asp Lys Ala Met Leu Phe Thr Tyr Asp Gln Tyr Gln
Glu Asn 180 185 190Asn Val Asp Gln Ala Ser Gly Ser Val Leu Leu His
Leu Glu Val Gly 195 200 205Asp Gln Val Trp Leu Gln Val Tyr Gly Glu
Gly Glu Arg Asn Gly Leu 210 215 220Tyr Ala Asp Asn Asp Asn Asp Ser
Thr Phe Thr Gly Phe Leu Leu Tyr225 230 235 240His Asp Thr
Asn31276DNAMus musculusCDS(46)..(789) 3ctctaaagat tgtcagtgga
tctgacgaca ccaaaagggc tcagg atg cta ctg ttg 57 Met Leu Leu Leu 1caa
gct ctc ctg ttc ctc tta atc ctg ccc agt cat gcc gaa gat gac 105Gln
Ala Leu Leu Phe Leu Leu Ile Leu Pro Ser His Ala Glu Asp Asp5 10 15
20gtt act aca act gaa gag cta gct cct gct ttg gtc cct cca ccc aag
153Val Thr Thr Thr Glu Glu Leu Ala Pro Ala Leu Val Pro Pro Pro Lys
25 30 35gga act tgt gca ggt tgg atg gca ggc atc cca gga cat cct ggc
cac 201Gly Thr Cys Ala Gly Trp Met Ala Gly Ile Pro Gly His Pro Gly
His 40 45 50aat ggc aca cca ggc cgt gat ggc aga gat ggc act cct gga
gag aag 249Asn Gly Thr Pro Gly Arg Asp Gly Arg Asp Gly Thr Pro Gly
Glu Lys 55 60 65gga gag aaa gga gat gca ggt ctt ctt ggt cct aag ggt
gag aca gga 297Gly Glu Lys Gly Asp Ala Gly Leu Leu Gly Pro Lys Gly
Glu Thr Gly 70 75 80gat gtt gga atg aca gga gct gaa ggg cca cgg ggc
ttc ccc gga acc 345Asp Val Gly Met Thr Gly Ala Glu Gly Pro Arg Gly
Phe Pro Gly Thr85 90 95 100cct ggc agg aaa gga gag cct gga gaa gcc
gct tat atg tat cgc tca 393Pro Gly Arg Lys Gly Glu Pro Gly Glu Ala
Ala Tyr Met Tyr Arg Ser 105 110 115gcg ttc agt gtg ggg ctg gag acc
cgc gtc act gtt ccc aat gta ccc 441Ala Phe Ser Val Gly Leu Glu Thr
Arg Val Thr Val Pro Asn Val Pro 120 125 130att cgc ttt act aag atc
ttc tac aac caa cag aat cat tat gac ggc 489Ile Arg Phe Thr Lys Ile
Phe Tyr Asn Gln Gln Asn His Tyr Asp Gly 135 140 145agc act ggc aag
ttc tac tgc aac att ccg gga ctc tac tac ttc tct 537Ser Thr Gly Lys
Phe Tyr Cys Asn Ile Pro Gly Leu Tyr Tyr Phe Ser 150 155 160tac cac
atc acg gtg tac atg aaa gat gtg aag gtg agc ctc ttc aag 585Tyr His
Ile Thr Val Tyr Met Lys Asp Val Lys Val Ser Leu Phe Lys165 170 175
180aag gac aag gcc gtt ctc ttc acc tac gac cag tat cag gaa aag aat
633Lys Asp Lys Ala Val Leu Phe Thr Tyr Asp Gln Tyr Gln Glu Lys Asn
185 190 195gtg gac cag gcc tct ggc tct gtg ctc ctc cat ctg gag gtg
gga gac 681Val Asp Gln Ala Ser Gly Ser Val Leu Leu His Leu Glu Val
Gly Asp 200 205 210caa gtc tgg ctc cag gtg tat ggg gat ggg gac cac
aat gga ctc tat 729Gln Val Trp Leu Gln Val Tyr Gly Asp Gly Asp His
Asn Gly Leu Tyr 215 220 225gca gat aac gtc aac gac tct aca ttt act
ggc ttt ctt ctc tac cat 777Ala Asp Asn Val Asn Asp Ser Thr Phe Thr
Gly Phe Leu Leu Tyr His 230 235 240gat acc aac tga ctgcaactac
ccatagccca tacaccagga gaatcatgga 829Asp Thr Asn245acagtcgaca
cactttcagc ttagtttgag agattgattt tattgcttag tttgagagtc
889ctgagtatta tccacacgtg tactcacttg ttcattaaac gactttataa
aaaataattt 949gtgttcctag tccagaaaaa aaggcactcc ctggtctcca
cgactcttac atggtagcaa 1009taacagaatg aaaatcacat ttggtatggg
ggcttcacaa tattcgcatg actgtctgga 1069agtagaccat gctatttttc
tgctcactgt acacaaatat tgttcacata aaccctataa 1129tgtaaatatg
aaatacagtg attactcttc tcacaggctg agtgtatgaa tgtctaaaga
1189cccataagta ttaaagtggt agggataaat tggaaaaaaa aaaaaaaaaa
aagaaaaact 1249ttagagcaca ctggcggccg ttactag 12764247PRTMus
musculus 4Met Leu Leu Leu Gln Ala Leu Leu Phe Leu Leu Ile Leu Pro
Ser His1 5 10 15Ala Glu Asp Asp Val Thr Thr Thr Glu Glu Leu Ala Pro
Ala Leu Val 20 25 30Pro Pro Pro Lys Gly Thr Cys Ala Gly Trp Met Ala
Gly Ile Pro Gly 35 40 45His Pro Gly His Asn Gly Thr Pro Gly Arg Asp
Gly Arg Asp Gly Thr 50 55 60Pro Gly Glu Lys Gly Glu Lys Gly Asp Ala
Gly Leu Leu Gly Pro Lys65 70 75 80Gly Glu Thr Gly Asp Val Gly Met
Thr Gly Ala Glu Gly Pro Arg Gly 85 90 95Phe Pro Gly Thr Pro Gly Arg
Lys Gly Glu Pro Gly Glu Ala Ala Tyr 100 105 110Met Tyr Arg Ser Ala
Phe Ser Val Gly Leu Glu Thr Arg Val Thr Val 115 120 125Pro Asn Val
Pro Ile Arg Phe Thr Lys Ile Phe Tyr Asn Gln Gln Asn 130 135 140His
Tyr Asp Gly Ser Thr Gly Lys Phe Tyr Cys Asn Ile Pro Gly Leu145 150
155 160Tyr Tyr Phe Ser Tyr His Ile Thr Val Tyr Met Lys Asp Val Lys
Val 165 170 175Ser Leu Phe Lys Lys Asp Lys Ala Val Leu Phe Thr Tyr
Asp Gln Tyr 180 185 190Gln Glu Lys Asn Val Asp Gln Ala Ser Gly Ser
Val Leu Leu His Leu 195 200 205Glu Val Gly Asp Gln Val Trp Leu Gln
Val Tyr Gly Asp Gly Asp His 210 215 220Asn Gly Leu Tyr Ala Asp Asn
Val Asn Asp Ser Thr Phe Thr Gly Phe225 230 235 240Leu Leu Tyr His
Asp Thr Asn 245
* * * * *